| Ytd | -18.80% | |
| 1y | -48.57% |
| Open | Prev Close | 1.08 | Low | High | Mkt Cap | 37.13M | |||
| Vol | 0.00 | Avg Vol | 154.54K | EPS | -0.29 | P/E | -3.72 | Forward P/E | N/A |
| Beta | -0.25 | Short Ratio | 5.77 | Inst. Own | 6.92% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 1.25 | 200-d Avg | 1.33 | 1yr Est | 12.15 |
TELO News
Gainers China Pharma Holding (AMEX:CPHI) shares increased by 713.2% to $7.4 during Tuesday's re
Gainers iTonic Holdings (NASDAQ:ITOC) stock increased by 8.1% to $0.3 during Friday's after-mar
Insulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose
Study Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Redu
Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Acad
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO - Get Free Report) shares traded up 1.4% during trading
Transaction establishes global ownership rights of lead program and includes initial capital funding
Telomir Pharmaceuticals (NASDAQ: TELO - Get Free Report) and Jaguar Animal Health (NASDAQ: JAGX - Ge
First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinica
Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cyto
Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress,
Telomir Pharmaceuticals (NASDAQ: TELO - Get Free Report) is expected to be issuing its results befor
electroCore (NASDAQ: ECOR - Get Free Report) and Telomir Pharmaceuticals (NASDAQ: TELO - Get Free Re
In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistic
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO - Get Free Report) was down 8.9% on Monday. The stock tr
No treatment-related adverse toxicity was observed across completed GLP studies, with consistent sys
PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response;
Findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reporte
New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicro
New findings highlight Telomir-1's impact on CASP8 and GSTP1, two critical genes that regulate cell
Unifying global IP rights and enabling up to $5 million in potential shareholder contributions, the
Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostat
